Business Wire

Armis Expands Technology Partner Ecosystem to Help Global Organizations Fortify Cyber Defenses

12.11.2025 15:00:00 EET | Business Wire | Press release

Share

Armis, the cyber exposure management & security company, today announced 11 new global technology integration partners. These integrations enhance joint customers’ existing technology stacks, enabling them to streamline security operations and reduce their cyber risk exposure.

“The era of fragmented security is over – organizations demand best-in-class solutions that work seamlessly together to solve today's most complex cybersecurity challenges,” said Nadir Izrael, CTO and Co-Founder at Armis. “By partnering with other industry leaders, we are not just integrating tools; we are delivering a unified security ecosystem that reduces complexity and empowers joint customers to optimize their technology investments. This supports businesses in staying ahead of threats and protecting their most critical assets with confidence.”

New Armis global technology integration partners include BlastWave, Cato Networks, Checkmarx, CyCognito, Elastic, Onyxia Cyber, Profitap, TeamDynamix, Tines, Sygnia, and Virsec. These new integrations further strengthen Armis' partner ecosystem, expanding on the growth announced earlier this year, and bring immediate value to joint customers:

  • “The joint solution is a game-changer for our customers. By leveraging insights from Armis Centrix™ and the Cato SASE Platform, we enhance visibility, classification, and policy definition – empowering security teams to identify and then protect Internet of Things (IoT) and operational technology (OT) devices in factories and offices across the globe from one console.” –Ofir Agasi, Chief Product Officer of Cato Networks
  • Together, Armis and CyCognito are bridging the gap between external and internal exposures and identifying attackers’ path of least resistance. By integrating CyCognito’s external attack surface management platform with Armis Centrix™, we are delivering the industry’s first truly comprehensive internal and external exposure management solution. This enables joint customers to map critical attack paths, prioritize based on real-world exploitability and accelerate remediation.” –Rob Gurzeev, CEO of CyCognito
  • IoT and unmanaged assets remain some of the most challenging blind spots for security teams today. Armis’ deep contextual insights, combined with Elastic's open and extensible platform and its AI-driven SOC operations, enable analysts to bring in any data for faster detection, smarter investigations, and quicker responses, all in one place. –Mike Nichols, GM of Elastic Security
  • “In complex cyber crises, speed and context are everything. When Sygnia begins incident response efforts with an organization that has already deployed the Armis Centrix™ platform, our responders can tap its comprehensive, real-time visibility across managed and unmanaged assets. This enhanced context accelerates investigations and recovery planning, helping organizations return to business faster and stronger.” –Guy Segal, CEO of Sygnia

Armis continues to experience great demand driven by its award-winning Cyber Exposure Management Platform, Armis Centrix™. Most recently, the company was named a Leader in The Forrester Wave™: IoT Security Solutions, Q3 2025 and The Forrester Wave™: Unified Vulnerability Management Solutions, Q3 2025. Armis was also recognized earlier this year as a Leader in the Gartner® Magic Quadrant™ for CPS Protection Platforms.

Additional partner organizations shared the following benefits of working with Armis:

  • “At Profitap, we’re dedicated to delivering uncompromised network visibility and performance at scale. Our integration with Armis Centrix™ takes that mission further, turning lossless network data into real-time, actionable intelligence. By combining Profitap’s reliable traffic access with Armis’ deep asset intelligence and automated threat response, organizations gain complete visibility across every network layer, eliminating blind spots and empowering faster, more confident security decisions.” –Geoffrey Kempenich, CEO of Profitap
  • “Security teams need both speed and comprehensive insights to stay ahead of evolving threats. By combining Armis’ real-time asset intelligence with Tines intelligent workflows, teams can uncover unseen risks, orchestrate responses, and strengthen their security posture across the entire environment.” –John Schimelpfenig, Director, Technology Partnerships of Tines

Learn more about Armis’ global technology integration partners here.

About Armis

Armis, the cyber exposure management & security company, protects the entire attack surface and manages the organization’s cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets – from the ground to the cloud. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251112892711/en/

Contacts

Media Contacts:
Rebecca Cradick
Vice President, Global Communications
Armis
pr@armis.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye